Boston Scientific cut its full-year outlook after two of its core heart-disease products faced unexpected challenges in the ...
Confusion over when and if to use the Watchman implant to reduce stroke risks in patients with irregular heartbeats is hurting Boston Scientific — and could put the Twin Cities in the crosshairs of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results